Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

Background: The optimal adjuvant endocrine treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) early breast cancer (eBC) remains debated, particularly the choice between aromatase inhibitors plus ovarian function suppression (AI + OFS) or tamoxifen (TAM)...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Volkmar Müller, Manuel Hörner, Marc Thill, Maggie Banys-Paluchowski, Sabine Schmatloch, Peter A. Fasching, Nadia Harbeck, Dagmar Langanke, Sabrina Uhrig, Lothar Häberle, Dorothea Fischer, Alexander Hein, Tanja N. Fehm, Chloë Goossens, Jürgen Terhaag, Uwe Heilenkötter, Peter Dall, Christian Rudlowski, Rachel Wuerstlein, Mustafa Aydogdu, Mignon-Denise Keyver-Paik, Carolin Hammerle, Natalija Deuerling, Elmar Stickeler, Bahriye Aktas, Erik Belleville, Martin Thoma, Nina Ditsch, Yasmin Baila, Christian Roos, Christian Mann, Caterina Iuliano, Sara Y. Brucker, Andreas Schneeweiss, Andreas D. Hartkopf
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-06-01
Serie:	Breast
Ämnen:	Early breast cancer Endocrine therapy Tamoxifen Aromatase inhibitor Hormone receptor-positive
Länkar:	http://www.sciencedirect.com/science/article/pii/S0960977625004758
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!